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Abstract
Background and purpose Randomized trials confirmed the efficacy and the safety of hypofractionated whole breast irradia-
tion (HF-WBI) in patients with early-stage breast cancer. However, the role of HF-WBI in patients with DCIS after breast 
conserving surgery has not yet been clearly established in prospective randomized trials. The aim of this study was to evaluate 
if HF-WBI can be considered comparable to conventionally fractionated (CF)-WBI in DCIS patients.
Materials and methods The analysis included DCIS patients from four Italian centers treated with CF-WBI 50 Gy/25 frac-
tions or HFRT 40.5 Gy/15 fractions, without tumor bed boost. A propensity score matching (PSM) analysis was performed 
using a logistic regression that considered age, grading, presence of necrosis, resection margin status and adjuvant endocrine 
therapy.
Results Five hundred twenty-seven patients was included (367 in the CF-WBI-group and 160 in the HR-WBI group). After 
1:1 matching, 101 patients were allocated to the CF-WBI-group and 104 to the HF-WBI group. No correlation was observed 
between the type of RT schedule and LRFS (HR 1.68, 95% CI 0.82–3.45; p = 0.152). After PSM, no statistical difference 
was observed between the two RT group (HR 1.11, 95% CI 0.40–3.04; p = 0.833), with 3- and 5-years LRFS rates of 100% 
and 97.9% for CF-WBI and 95.6% and 94% for HF-WBI.
Conclusion A short course of radiation therapy seems to be comparable to CF-WBI in terms of clinical outcomes. These 
data support the use of hypofractionated schedules in DCIS patients, but considering the remaining uncertainties.
Keywords Ductal carcinoma in situ · Breast cancer · Hypofractionated radiotherapy · Multicenter study · Propensity score 
matching
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Introduction
The increasing use of diagnostic screening and advances 
in breast imaging led to a progressive increase of detection 
rate of ductal carcinoma in situ (DCIS) (Kerlikowske 2010). 
DCIS is a noninvasive variant of breast cancer with a negli-
gible likelihood to develop regional lymph nodes localiza-
tion or distant metastases (Sanders et al. 2005). However, the 
natural history of this clinical entity is unclear: certain cases 
are indolent but others can progress into invasive disease 
(Wallis et al. 2012). Historically, the conservative manage-
ment of DCIS included breast conserving surgery (BCS) and 
whole breast irradiation (WBI) as postoperative treatment 
to achieve a significant local control benefit (Cuzick et al. 
2011; Donker et al. 2013; McCormick et al. 2015; Wapnir 
et al. 2011; Warnberg et al. 2014). The major randomized 
trials adopted conventionally fractionated WBI (CF-WBI), 
and the schedule of 50 Gy in 25 fractions (5 fractions a week 
over 5 weeks) represented for decades the standard treatment 
for these patients.
The role of hypofractionation (HF) was investigated in 
patients with early-stage invasive breast cancer and the long-
term results of the major clinical studies showed no signifi-
cant differences in efficacy and toxicity as compared to CF-
WBI (Haviland et al. 2013; Whelan et al. 2010). Therefore, 
HF-WBI has become the preferred radiation scheme for the 
treatment of early-stage invasive breast cancer (Smith et al. 
2018).
Even more, after the recent publication of the results of 
the FAST-Forward trial (Murray Brunt et al. 2020), 1-week 
regimen instead of a standard 3-weeks schedule may be con-
sidered for a substantial group of patients. Considering the 
available literature data, the radiobiological bases common 
to both invasive and in situ breast cancer (Owen et al. 2006; 
Yarnold et al. 2005), and the standard use of HF-WBI in 
invasive breast carcinoma, the rationale to offer HF-WBI to 
breast cancer patients affected with DCIS is getting stronger.
Nevertheless, the role of HF-WBI in this setting is still 
debated, since data from randomized trials are pending and 
the level of evidence is low (Isfahanian et al. 2017; Lalani 
et al. 2014; Nilsson and Valachis 2015; Williamson et al. 
2010).
We therefore performed a propensity score matching 
analysis (PSM) to evaluate whether HF-WBI can be consid-
ered comparable to CF-WBI in DCIS patients after breast 
conservation, based on a multicentric database.
Materials and methods
Study design and participants
We collected data from four Italian centers on women with 
DCIS and treated with BCS and postoperative radiation 
therapy (RT). Adjuvant endocrine therapy (ET) administra-
tion, RT fractionation, and delivery of a boost dose to the 
tumor bed followed the local policy of each Institution. The 
CF-WBI schedule was 50 Gy in 25 fractions over 5 weeks; 
the HF-WBI regimen was 40.5 Gy, 2.7 Gy per fraction in 15 
fractions over 3 weeks.
Statistical analysis and propensity score matching
Distribution of clinical characteristics was analyzed using 
percentiles for continuous variables, and percentages and 
frequencies for categorical variables. Local recurrence free 
survival (LRFS) was defined as the time between the day of 
surgery and the date of locoregional recurrence, death from 
any cause or last follow-up. Distant metastases-free survival 
(DMFS) was considered as the time between surgery and 
diagnosis of metastases, death from any cause or last follow-
up. Overall survival (OS) was defined as the time between 
date of surgery RT and death from any cause or last follow-
up. We used Kaplan–Meier method to assess survival and 
log-rank statistic to test for differences between the patient 
and treatment’s characteristics. All the analyses were per-
formed using STATA V13 software (STATA Corp, College 
Station, TX).
We aimed to standardize the groups based on propensity 
to receive one RT treatment schedule over another. The fol-
lowing variables were selected: age (> or < 50 years), grad-
ing, presence of necrosis, resection margin status (negative 
vs close/positive) and endocrine therapy administration. A 
small subgroup of patients that received a radiotherapy boost 
to the lumpectomy cavity was excluded from the present 
analysis.
To minimize selection bias inherent in treatment group 
allocation, propensity score modeling was used to match the 
two groups using a logistic regression approach. An absolute 
standard bias measure < 0.20 is considered small, and suf-




Data on 527 DCIS patients treated with BCS and postop-
erative RT between 1989 and 2017 were analyzed (DCIS 
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patients that received HF-WBI were treated from 2013 to 
2017). Before PSM 367 were allocated to the CF-WBI and 
160 to the HF-WBI groups, respectively. Patient charac-
teristics of the whole cohort are reported in Table 1. After 
1:1 matching, 101 patients were comprised in the CF-WBI 
group and 104 in the HF-WBI group. Prognostic variables 
before and after PSM are summarized in Table 2.
Median follow-up time was 128.1 months (range 6–352.4) 
for the whole sample. Median follow-up was 151.2 months 
for the CF-WBI group and 44.9 months for the HF-WBI 
group.
Local recurrence‑free survival analysis
Among all patients, 58 (11.01%) had local relapse (48 in the 
CF-WBI group and 10 in the HF-WBI group). Median LRFS 
was not reached. Rates of LRFS at 3 and 5 years were 97.9% 
(95% CI 96.2–98.9) and 95.9% (95% CI 93.6–97.3), respec-
tively. At analysis of correlation of risk factors with LRFS, 
higher grade (HR 1.85, 95% CI 1.23–2.77; p = 0.003) and 
positive margins (HR 1.99, 95% CI 1.06–3.73; p = 0.031) 
were correlated with worse LRFS. No correlation was 
observed between RT schedule and LRFS (HR 1.68, 95% CI 
0.82–3.45; p = 0.152). For CF-WBI, 3 and 5 year LRFS were 
98.6% (95% CI 96.7–99.4) and 97.2% (95% CI 94.9–98.5), 
respectively, while they were 95.8% (95% CI 90.2–98.2) 
and 91.3% (95% CI 83.3–95.4) for HF-WBI (Fig. 1a). After 
PSM, no statistical difference was observed between the two 
RT group (HR 1.11, 95% CI 0.40–3.04; p = 0.833) as well. 
Three and 5 years LFRS rates were 100% and 97.9% (95% 
CI 92.2–99.4) for CF-WBI and 95.6% (88.7–98.3) and 94% 
(95% CI 86–97.5) for HF-WBI (Fig. 1b), respectively.
Overall survival analysis
Rates of OS at 3 and 5 years were 99.5% (95% CI 98.3–99.9) 
and 99.1% (95% CI 97.6–99.6). At univariate analysis, only 
positive resection margin was correlated with worse OS (HR 
2.67, 95% CI 1.31–5.43; p = 0.006). No statistical differ-
ence was demonstrated for RT treatment (HR 0.62, 95% CI 
1.47–2.62; p = 0.519). According to treatment group, 3 and 
5 years rates were 99.7% (95% CI 98–99.9) and 99.1% (95% 
CI 97.4–99.7) for CF-WBI and 98.9% (95% CI 93–99.8) 
and 98.9% (95% CI 93–99.8) for HF-WBI (Fig. 2a). After 
PSM, there were no difference (HR 0.50; 95% CI 0.1–2.26; 
p = 0.371) in terms OS between the two groups with 3- and 
5-years rates of 100% for CF-WBI, and 98.7% (95% CI 
91.4–99.8) for HF-WBI (Fig. 2b).
Distant metastasis‑free survival analysis
Median DMFS was not reached. DMFS rate was 99.5% 
(95% CI 98.3–99.9) and 99.3% (95% CI 98–99.7) at 3 and 
5 years. At univariate analysis, none of the analyzed factors 
was correlated with DMFS. Rates of DMFS were 100% at 
3 and 5 years for CF-WBI and 98.4% (95% CI 93.8–99.6) 
and 97.2% (95% CI 91.6–99.1) for HF-WBI (Fig. 3a). After 
PSM, RT treatment was not correlated with DMFS (HR 
1.44, 95% CI 0.22–9.28; p = 0.701) (Fig. 3b).
Discussion
Large randomized trials confirmed with a considerable fol-
low-up the equivalence of CF-WBI and HF-WBI in terms 
of efficacy and toxicity for patients with early-stage breast 
cancer (Haviland et al. 2013; Whelan et al. 2010).
Table 1  Patients characteristics of the whole cohort
CF-WBI conventionally fractionated WBI, HF-WBI hypofractionated 
WBI
All patients CF-WBI HF-WBI
527 pts 367 pts 160 pts
Age years, median (range) 57 (31–83) 58 (30–87) 57 (30–87)
Family history
 No 344 (65.3) 240 (65.4) 104 (65)
 Yes 180 (34.2) 124 (33.8) 56 (35)
 ND 3 (0.5) 3 (0.8) 0
Radiological presentation
 No 41 (7.8) 27 (7.3) 14 (8.7)
 Yes 484 (92.0) 339 (92.4) 145 (90.6)
 ND 1 (0.2) 1 (0.3) 1 (0.6)
Menopausal state
 Premenopausal 152 (28.8) 100 (27.2) 52 (32.5)
 Postmenopausal 375 (71.2) 267 (72.8) 108 (67.5)
N° excision
 0 15 (2.8) 11 (3.0) 4 (2.5)
 1 511 (97.0) 355 (96.7) 156 (97.5)
 2 1 (0.2) 1 (0.3) 0
Grading
 1 97 (18.1) 79 (21.5) 18 (11.2)
 2 181 (33.8) 102 (27.8) 79 (49.4)
 3 249 (46.4) 186 (50.7) 63 (39.3)
Necrosis
 No 272 (51.6) 155 (42.2) 117 (73.1)
 Yes 255 (48.4) 212 (57.8) 43 (26.9)
Margins
 Negative 451 (85.4) 311 (84.7) 140 (87.5)
 Positive 76 (14.6) 56 (15.3) 20 (12.5)
Endocrine therapy
 No 398 (75.5) 254 (69.2) 144 (90)
 Yes 129 (24.5) 113 (30.8) 16 (10)
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These data led radiation oncologist to evaluate HF-WBI 
as postoperative treatment for DCIS patients in their clini-
cal practice.
There are retrospective and observational studies on series 
of DCIS patients treated with hypofractionated schemes that 
reported local recurrence rates ranging between 0 and 4.1% 
at 2–5 years (Cante et al. 2014; Ciervide et al. 2012; De Rose 
et al. 2018; Guenzi et al. 2013; Hathout et al. 2013).
Recently, the long-term results of Danish Breast Cancer 
Group (DBCG) HYPO trial, including 246 patients with 
DCIS, showed the non-inferiority of moderate hypofraction-
ated schedule compared with conventional scheme in terms 
of breast induration or locoregional recurrence, but this was 
not the primary end-point of this trial (Offersen et al. 2020). 
However, these are the first encouraging data on the largest 
cohort of randomly assigned patients with DCIS.
An international, multicenter, randomized, phase 3 trial 
(BIG 03–07/TROG 07.01) is ongoing to evaluate the role 
of tumor bed boost and hypofractionation in patients with 
non-low-risk DCIS. The effects of diagnosis and treatment 
on health-related quality of life (HRQoL) at 2 years were 
recently published (King et al. 2020; Olivotto et al. 2020), 
but the results in terms of time to local recurrence (primary 
endpoint of the study) are still pending.
Waiting for mature randomized data, different authors 
reported retrospective analyses of DCIS patient series com-
paring HF-WBI and CF-WBI (Isfahanian et al. 2017; Lalani 
et al. 2014; Williamson et al. 2010) and all confirmed a sub-
stantial equivalence in terms of LC rates. Particularly, the 
Canadian group (Lalani et al. 2014) published comparative 
data on the largest DCIS population cohort that reported 
a not significant difference in local recurrence in HF-WBI 
group.
In 2015, a meta-analysis of observational studies con-
firmed HF-WBI as a safe option in patients with DCIS (Nils-
son and Valachis 2015). More recently, the American Soci-
ety of Radiation Oncology recommended with a moderate 
quality of evidence HF-WBI as an alternative to CF-WBI in 
patients with DCIS (Smith et al. 2018).
In this context, we aimed to compare clinical outcomes 
of two cohort of DCIS patients treated with CF-WBI or HF-
WBI from an Italian multicenter database, using a propen-
sity score matching to reduce the selection bias.
During the last decades, clinical, histopathological and 
treatment-related features were identified and included into 
nomograms to predict local recurrence risk (Meattini et al. 
2019; Mokbel and Cutuli 2006; Rakovitch et al. 2007).
In our study, higher grade and positive surgical margins 
were confirmed to be correlated with worse LRFS.
Table 2  Prognostic variables 
before and after propensity 
score matching (PSM)
CF-WBI conventionally fractionated WBI, HF-WBI hypofractionated WBI
Before PSM After PSM
CF-WBI HF-WBI P value CF-WBI HF-WBI P value
367 pts 160 pts 101 pts 104 pts
Age 0.052 0.898
  ≤ 50 79 47 27 28
  > 50 288 113 73 76
Grading 0.000 0.991
 1 79 18 17 17
 2 102 79 45 46
 3 186 63 39 41
Necrosis 0.000 0.872
 No 155 117 63 66
 Yes 212 43 38 38
Margins 0.407 0.942
 Negative 311 140 90 93
 Positive 56 20 11 11
Endocrine therapy 0.000 0.939
 No 254 144 89 92
 Yes 113 16 12 12
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After the application of PSM, the distribution of the main 
prognostic factors, such as age, grading, resection margin 
status, was comparable in the two RT treatment groups con-
firming the homogeneity of the analyzed samples.
In both arms, we excluded patients that received a 
tumor bed boost (TBB), whereas endocrine therapy was 
administered to a small numbers of patients (13% of each 
cohort after PSM). In the previously cited publications, the 
use of boost dose and the administration of tamoxifen were 
different in the HF-WBI and CF-WBI groups. Williamson 
(Williamson et al. 2010) included TBB only in one of the 
two hypofractionated schedules; whereas, endocrine therapy, 
Fig. 1  a LRFS Kaplan–Meier 
curves before PSM. CRT 
conventionally fractionated 
radiotherapy, HRT hypofrac-
tionated radiotherapy. b LRFS 
Kaplan–Meier curves after 
PSM. CRT conventionally 
fractionated radiotherapy, HRT 
hypofractionated radiotherapy
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administered in 15.7% of patients, resulted well balanced in 
both cohorts. In the study by Lalani et al. (2014), TBB was 
more frequently prescribed in the HF group, although they 
use propensity score matching to mitigate this imbalance. 
Moreover, the authors declared the absence of information 
about tamoxifen use for women younger than 65 years as 
an important limitation of their study. On the other hand, 
Isfahanian and colleagues (2017) reported comparable rate 
of TBB in HF (31%) and CF (23%) cohorts; similarly, endo-
crine therapy was administered in 27% of HF group and in 
22% of CF group.
Regarding clinical outcomes, our study did not show any 
significant differences in terms of LRFS, DMFS and OS at 
3 and 5 years in both unmatched and matched population, 
according to the literature. We found that 3 and 5 years LRFS 
rate were slightly lower in women treated with HF-WBI than 
in those treated with CF (95.6–94% vs 100–0.97.9%). How-
ever, 5-years LRFS rate of our HF cohort was substantially 
comparable with those reported for the same group (HF) in 
the aforementioned studies (Isfahanian et al. 2017; Lalani 
et al. 2014).
Fig. 2  a OS Kaplan–Meier 
curves before PSM. CRT 
conventionally fractionated 
radiotherapy, HRT hypofrac-
tionated radiotherapy. b OS 
Kaplan–Meier curves after 
PSM. CRT conventionally 
fractionated radiotherapy, HRT 
hypofractionated radiotherapy
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Previously, Lalani et al. made a comparison between the 
two treatments using a propensity score adjustment approach 
(Austin 2011). To the best of our knowledge, our study is the 
first to use a propensity score matching method to compare 
two different radiotherapy schedules for DCIS patients. In 
this case, matched sets of treated subjects who share a simi-
lar value of the propensity score were defined (Rosenbaum 
and Rubin 1983), to minimize the selection bias thus well 
balanced in the studied cohorts.
As our analysis inevitably has some limitations (above 
all the retrospective nature of the collected data, then the 
limited number of the HF-WBI sample and finally the short 
follow-up period of the HF-WBI cohort) there is still some 
uncertainty about the long-term outcome which is relevant 
in a patient cohort with high longevity as it is the case for 
DCIS patients. The pending phase III results will further 
solidify the data basis for this disease paradigm.
Fig. 3  a DMFS Kaplan–Meier 
curves before PSM. CRT 
conventionally fractionated 
radiotherapy; HRT hypofrac-
tionated radiotherapy. b DMFS 
Kaplan–Meier curves after 
PSM. CRT conventionally 
fractionated radiotherapy; HRT 
hypofractionated radiotherapy
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Conclusion
Our PSM analysis confirmed that a HF-WBI schedule is 
comparable to CF-WBI in terms of efficacy for DCIS 
patients undergoing BCS. Waiting for the results of ongo-
ing phase III randomized trials, these data support the use of 
hypofractionated schedules in DCIS patients, but consider-
ing the remaining uncertainties. The appropriate total dose 
and the necessity for a tumor bed boost will also be further 
elucidated by the pending phase III results.
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